Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (1190)	4/29/2003 6:52:09 PM
From: John McCarthy	Respond to of 1494

Marc - Thanks for asking about it. btw - a poster on Yahoo informed me that jmdutton is coming out with a recommendation on AXYX and hence the 60% or so run-up in the stock the last two days. Additionally, another poster posted the following: Did you happen to notice that one of the board members is Abraham Cohen i.e. the same guy who is Chairman of NTI? Also, one of the two NYU professors that led the Forest Phase III is on the BoD. I think it's Steven Ferris but don't hold me to it. Lastly, a couple members of Axonyx's management team were with Forest previously. Is all this coincidence? Maybe, maybe not. Given how well Axonyx has done the last few days, I'm beginning to wonder. messages.yahoo.com and this .... I went to Axonyx website. I was correct about Cohen and Ferris being on the BoD. The COO of Axonyx, last name Bruinsma, had a stint at Forest as Medical Director during the mid-90's. I thought there was another former Forest person, but I can't seem to find one now. Still, the connections are compelling. messages.yahoo.com finally - a really nice surprize - Dr Dec posted and directed his post towards another San Fran Neuro doctor who goes by the handle myrinx ... (I think the reason for the post is self-evident) Myrinx, Paul is far too savvy to sell the company for $14 per share. He knows its worth and will not sell it for less. That is why it hasn't been sold yet. He's not offering a bargain. Look at the man's negotiating history. He has always negotiated well and produced fair results for all parties involved. Look at Syntek or to the deal with Merz and Forest for memantine. Fourteen dollars per share would not get his interest, unless the DN trial is negative. Forest Labs is not that interested in NTI. They want new drugs to market. They have plenty of cash. NTI offers plenty of cash, but no new drugs. The best match for NTI will be a company with excellent late stage drugs in development, but lacking in cash. Just my humble opinion. Best regards John de C messages.yahoo.com back to the blanket .... regards, John